Fluoxetine

• UNSPSC Description:

  Fluoxetine (LY-110140 free base) is a selective serotonin reuptake inhibitor (SSRI) class used for antidepressant research.

• Target Antigen:

  Autophagy; Serotonin Transporter

• Type:

  Reference compound

• Related Pathways:

  Autophagy;Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/fluoxetine.html

• Purity:

  99.87

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  FC(C1=CC=C(OC(C2=CC=CC=C2)CCNC)C=C1)(F)F

• Molecular Weight:

  309.33

• References & Citations:

  [1]Malberg JE, et al. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology. 2003 Sep;28(9):1562-71|[2]Kodama M, et al. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry. 2004 Oct 15;56(8):570-80.|[3]Wang JW, et al. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci. 2008 Feb 6;28(6):1374-84.|[4]Bymaster FP, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl). 2002 Apr;160(4):353-61|[5]Zhang W, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000 Sep;23(3):250-62.|[6]Avitsur R1. Increased symptoms of illness following prenatal stress: Can it be prevented by fluoxetine? Behav Brain Res. 2017 Jan 15;317:62-70.Behav Brain Res. 2017 Jan 15;317:62-70. |Behav Pharmacol. 2021 Jan 6.|Behav Pharmacol. 2024 Apr 24.|Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868.|Biochem Pharmacol. 2023 Oct 5:115846.|Biomedicines. 2023 Apr 26, 11(5), 1279.|Brain Behav Immun. 2021 Mar 15;S0889-1591(21)00114-8.|Cell Prolif. 2021 Jan;54(1):e12953.|Cell Rep. 2021 Nov 2;37(5):109957.|Chemosphere. 2019 Jun;225:378-387. |Eur J Pharmacol. 2019 Jan 15;843:260-267.|J Clin Psychopharmacol. 2021 Jun 11.|J Psychiatr Res. 2023 Oct 19.|J Transl Med. 2024 Aug 22;22(1):785.|Nat Med. 2019 Sep;25(9):1428-1441.|Orebro University. 2024.|Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 15;79(Pt B):258-267.|Research Square Preprint. 2023 Jun 16.|Research Square Preprint. 2023 Jun 29.|Virol J. 2024 Aug 8;21(1):181.|Fundam Clin Pharmacol. 2018 Aug;32(4):363-377.|J Neuroinflammation. 2017 Oct 30;14(1):210.|J Neuroinflammation. 2023 May 10;20(1):112.|Neuropharmacology. 2021 Feb 15;184:108410.|Neurotox Res. 2020 Dec;38(4):887-899.|Preprints. 2023 Dec 27.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  54910-89-3